
Sign up to save your podcasts
Or
In this interview, Andrew M. Kates, MD, FACC, and Alison L. Bailey, MD FACC, discuss the Top General CardiologyTakeaways from 2024. Dr. Kates discusses the 2024 Perioperative Guidelines, cardiac rehab, ACC’s proposal for a new Board of Cardiovascular Medicine, and more.
Bhave NM, Cibotti-Sun M, Moore MM. 2024 perioperative cardiovascular management for noncardiac surgery guideline-at-a-glance. J Am Coll Cardiol 2024;84:1970-75.
Pack OR, Keys T, Priya A, et al. Is 70% achievable? Hospital-level variation in rates of cardiac rehabilitation use among medicare beneficiaries. JACC Adv 2024;3:101275.
FDA Update: Acoramidis Approved to Reduce CV Death, Hospitalization in Patients With ATTR-CM (ACC.org). 2024. Available at https://www.acc.org/Latest-in-Cardiology/Articles/2024/11/26/15/02/fda-update-acoramidis-approved-to-reduce-cv-death-hospitalization-in-patients-with-attr-cm. Accessed 12/10/24.
Gillmore JD, Judge DP, Cappelli F, et al., on behalf of the ATTRibute-CM Investigators. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 2024;390:132-42.
Board of Cardiovascular Medicine (ACC.org). 2024. https://cvboard.org/. Accessed 12/10/24.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
3.8
4747 ratings
In this interview, Andrew M. Kates, MD, FACC, and Alison L. Bailey, MD FACC, discuss the Top General CardiologyTakeaways from 2024. Dr. Kates discusses the 2024 Perioperative Guidelines, cardiac rehab, ACC’s proposal for a new Board of Cardiovascular Medicine, and more.
Bhave NM, Cibotti-Sun M, Moore MM. 2024 perioperative cardiovascular management for noncardiac surgery guideline-at-a-glance. J Am Coll Cardiol 2024;84:1970-75.
Pack OR, Keys T, Priya A, et al. Is 70% achievable? Hospital-level variation in rates of cardiac rehabilitation use among medicare beneficiaries. JACC Adv 2024;3:101275.
FDA Update: Acoramidis Approved to Reduce CV Death, Hospitalization in Patients With ATTR-CM (ACC.org). 2024. Available at https://www.acc.org/Latest-in-Cardiology/Articles/2024/11/26/15/02/fda-update-acoramidis-approved-to-reduce-cv-death-hospitalization-in-patients-with-attr-cm. Accessed 12/10/24.
Gillmore JD, Judge DP, Cappelli F, et al., on behalf of the ATTRibute-CM Investigators. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 2024;390:132-42.
Board of Cardiovascular Medicine (ACC.org). 2024. https://cvboard.org/. Accessed 12/10/24.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
129 Listeners
313 Listeners
160 Listeners
853 Listeners
488 Listeners
21 Listeners
31 Listeners
89 Listeners
133 Listeners
1,071 Listeners
38 Listeners
169 Listeners
409 Listeners
35 Listeners
134 Listeners